Medgenics Share Discussion Threads

[237gmoney] 23/9/2013 14:18

Shares have started up in the US even before the open. Two trades gone through at $7.3 a share. I have never known that to happen here before.

I know it happened at GKP before the suspension was lifted after the recent court case but GKP are worth c.£1.8 billion when we are worth less than £200m.

Interesting to see how today finishes

[237gmoney] 22/9/2013 22:10

On the move now so will be interesting to see what happens when the US opens today. The shares closed above $7 a share on friday over there so not sure what that equates to over here but would guess we are slightly behind at the moment?

If it was to open up in the US we could see another good week here. Has been a long time coming but good things come to those who wait.

[pdt] 22/9/2013 18:24

It gives me a lot of confidence whenever I see an insider buying. They cannot buy if it falls foul of insider trading rules as Harold points out but all directors have insider knowledge which is greater than us outsiders. It's not a reason to invest on its own but combined with all the other investing metrics it is a good one to have in the mix.

However wealthy you are staking quarter of a million dollars of your own money on what is still an early stage small cap is a big vote of confidence. It would be nice to see more insider buying from others and a partner being announced as part of the US trials would be icing on the cake.

[237gmoney] 22/9/2013 18:08

hxxp://seekingalpha.com/article/1705172-medgenics-overlooked-biotech-stock-could-be-good-risk-reward-investment?source=feed

Investors in the biotechnology sector probably don't need any antidepressants. Many biotechnology stocks are namely among the best performing across the stock market. Over the last 5 years, the biotechnology index trackers tripled in price. But did all biotechnology companies flourish? We discovered a small company that Wall Street has forgotten about but in fact is well positioned to become one of the greatest developers of medical technology that allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases such as anemia and hepatitis C. The industry in which they operate is worth billions of dollars. The company is Medgenics (MDGN) and this article explains why this stock is a must have for investors who are searching for a highly skewed risk/reward investment.

Company overview

Medgenics was founded in 2000 in San Francisco as a medical technology and therapeutics company which engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump, a groundbreaking tissue-based platform technology for the production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases, including anemia, hepatitis, hemophilia, and other chronic diseases. This pump technology is a platform for endless indications. Therefore the company plans to develop a pipeline of products based on this technology to target the broader large and rapidly growing global protein therapy market. R&D and manufacturing operates in Misgav, Israel and U.S. manufacturing operates in San Francisco.

[237gmoney] 22/9/2013 17:20

Harold, not so sure about that. The US Trials are due to be announced any time soon and we all know this is coming just do not know where and on what terms. We are coming up to the end of the 3rd quarter so results will be due soon and Sol would not have been able to buy before they are announced.

I would expect more director buying next week? Yes the new guys have options but these have 10 year time bans so no real dilution on those coming to the market anytime soon.

Over 600k shares traded in the US on Friday which is the biggest volume this year. Next week if the buying continues we could rise quickly to 500p+ with a pause there until the news of the trials come out...

[haroldthegreat] 22/9/2013 11:47

cant be any good news about to be released otherwise his purchase would be insider trading! so no good news soon!

[jammytass] 22/9/2013 09:06

sol barer would not put his name and recruit the top guys unless he is very confident that the trials are going well and the cmpy has a blockbuster future

[pdt] 22/9/2013 08:49

You are correct. Sol Barer bought 20,000 on the 19th and now another 20,000 on the 20th bringing his holding to 47,000 shares plus options.

Interestingly he was the guy involved in recruiting the new people. He must be confident in the work they are doing and the future.

[zaksab] 22/9/2013 00:20

Sol Barer bought 40,000 shares in total.

[237gmoney] 21/9/2013 16:15

I go away to France for a week an look what happens!Just back so will some more research over the weekend. Understand your concerns SK but this does seem good news. The board were all getting on and new blood will invigorate this now. The news of the US Trials will really open this up to a wider audience and hopefully that is forthcoming soon

[pdt] 20/9/2013 23:11

Nice 20% rise in the UK and 11% in the US in after hours trades.

And some insider buying is also reported today on the NASDAQ website;


•Sol Barer, a director at medical technology and therapeutics company Medgenics (NYSEMKT:MDGN), bought 20,000 shares of company stock for $111,478.

[jammytass] 20/9/2013 15:10

all the big hitters are in place, this looks like the spring board for a very large cmpy just wait for the news to come out !!!!!!!!!!

[pdt] 20/9/2013 08:21

Up another 17% last night in the US and 50p so far today over here.

I tried to buy a small quantity online this morning and couldn't get any and usually I can.

SK has a good point about the option dilution but even fully diluted at $181m market cap this could seem cheap if they do succeed to take a share of the $20 billion a year market that they are aiming for (figures from facts at the top of this thread).

[zaksab] 19/9/2013 01:09

Agree. Though most of the options are well out the money, and the company will receive cash on exercise.

[zaksab] 18/9/2013 21:19

interesting management change...

[jammytass] 18/9/2013 06:09

yes looks like the results are due this year

[pdt] 17/9/2013 21:07

"We reported the launch and enrollment of the first patient in our Phase I/II proof-of-concept clinical study of INFRADURE in the treatment of hepatitis C in Israel, and look forward to reporting interim data from this study before year-end."

This sentence is from the second quarter results release last month.

[jammytass] 17/9/2013 20:08

"Our goals for the balance of 2013 will be to continue to advance the clinical development of EPODURE and INFRADURE in Israel and the U.S., to expand our leadership with experienced industry executives, to optimize our manufacturing process, to pursue potential partnership and licensing opportunities and to explore potential new indications for our Biopump autologous tissue technology," concluded Dr. Pearlman

[scyther] 17/9/2013 17:34

What timeframe did the company give to expect trial results by?

I seem to remember the company only saying roughly year end

[jammytass] 17/9/2013 16:34

when we get trial results this will go sky high

[fanboy1] 17/9/2013 16:02

Good to finally have some news - not the sort expected but news all the same! Seems to have been very well received based on share price rises.

[jammytass] 17/9/2013 09:38

you do not have so many new heavy hitters on board unless there is very good news on the cards, as you say a flurry of announcements will be on way and the
chances of very special rns is on its way!!!!!!!!

[pdt] 17/9/2013 07:03

And those appointments will do very well if the share price surges with all the options they have been awarded. But so will shareholders.

For a small market cap company with so many heavy hitters now associated with it either as management or advisers you just get the feeling it has tremendous potential.

Could their appointment delay any news that was coming or has it been held back awaiting their arrival and now there will be a flurry of announcements?

[jammytass] 16/9/2013 18:01

Medgenics (MDGN) announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, Cola joined the Medgenics' Board of Directors. Cola was most recently President of Shire plc's (SHPG) Specialty Pharmaceuticals business. Leaman was most recently Vice President of Commercial Assessment at Shire plc. Andrew Pearlman, Ph.D., the company's Founder and previously the company's President and CEO, has retired as of September 13, and is continuing to serve on the Board of Directors and as a senior advisor to the company. This executive team will be based in the U.S. R&D and manufacturing will continue to operate in Misgav, Israel and U.S. manufacturing will continue to operate in San Francisco.